Back
BioMarin Pharmaceutical Inc. (BMRN)
BiotechnologyBMRN · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$59.97
+0.37%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$1.77
ROE
4.5%
Gross margin
51.2%
Debt/Equity
0.23x
Revenue growth
2.8%
BioMarin Pharmaceutical Inc. — company intelligence
Earnings surprises
Q1 2026$0.54 vs $0.77 est-29.5%
Q4 2025$-0.24 vs $0.64 est-137.7%
Q3 2025$-0.16 vs $0.38 est-142.2%
Q2 2025$1.23 vs $0.85 est+44.4%
Insider activity · 90 days
9 buys2 sellsnet +61,811 shares
Walbert Timothy PBuy 7,490 · Jun 2, 2026
Bodem Barbara W.Buy 7,490 · Jun 2, 2026
CLARK IAN TBuy 7,490 · Jun 2, 2026
Recent SEC filings
4 — Insider transaction reportJun 4, 2026
4 — Insider transaction reportJun 4, 2026
4 — Insider transaction reportJun 4, 2026
Latest news
RBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $62 — Benzinga · 3d ago
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Shows Strong Value Potential with a 7/10 Overall Rating — ChartMill · 1w ago
Ascendis Pharma: Behind The Stock Surge — SeekingAlpha · 1w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About BioMarin Pharmaceutical Inc.
Weekly undervalued picks (like BMRN)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.